Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 6/20 | 1.00 |
| ▸ | CA2 | P00918 | 4/20 | 0.59 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8547530 | 0.86 | CYP2A6 (0.75) | CYP2A6CA2HDAC10HDAC11HDAC8 | |
| Hydrochloric Acid SCHEMBL23012014 | 0.84 | CYP2A6 (0.73) | CYP2A6CA2HDAC10HDAC11HDAC8 | |
| SCHEMBL4255979 | 0.83 | CYP2A6 (0.71) | CYP2A6CA2HDAC10HDAC11HDAC8 | |
| SCHEMBL29414360 | 0.81 | CYP2A6 (0.69) | CYP2A6CA2HDAC10HDAC11HDAC8 | |
| SCHEMBL2217042 | 0.81 | CYP2A6 (0.69) | CYP2A6CA2HDAC10HDAC11HDAC8 | |
| SCHEMBL3742332 | 0.81 | CYP2A6 (0.69) | CYP2A6CA2HDAC10HDAC11HDAC8 | |
| SCHEMBL31588788 | 0.80 | CYP2A6 (0.67) | CYP2A6CA2HDAC10HDAC11HDAC8 | |
| SCHEMBL28563290 | 0.78 | CYP2A6 (0.64) | CYP2A6CA2HDAC10HDAC11HDAC8 | |
| Oxalic Acid SCHEMBL8552499 | 0.78 | CYP2A6 (0.63) | CYP2A6CA2HDAC10HDAC11HDAC8 | |
| SCHEMBL3180021 | 0.78 | CYP2A6 (1.00) | CYP2A6CA2MAPTKEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101687913-B | Kallikrein 7 modulators | NOVARTIS AG | 2013-09-18 | — | — | CN | disclosed |
| US-20130028843-A1 | KALLIKREIN 7 MODULATORS | NOVARTIS AG (CH) | 2013-01-31 | — | — | US | disclosed |
| US-8309596-B2 | Kallikrein 7 modulators | NOVARTIS AG (CH) | 2012-11-13 | — | — | US | disclosed |
| US-20100256144-A1 | Kallikrein 7 modulators | NOVARTIS AG (CH) | 2010-10-07 | — | — | US | disclosed |
| EP-2170939-A1 | KALLIKREIN 7 MODULATORS | Novartis Ag (CH) | 2010-04-07 | — | — | EP | disclosed |
| CN-101687913-A | kallikrein 7 modulators | NOVARTIS AG | 2010-03-31 | — | — | CN | disclosed |
| WO-2009000878-A1 | KALLIKREIN 7 MODULATORS | NOVARTIS AG (CH) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130028843-A1 | KALLIKREIN 7 MODULATORS | KLK7, KLK5, KLKB1 | CYP2A6 2666/4885CA2 2618/4885HDAC10 1524/4885 |
| US-20100256144-A1 | Kallikrein 7 modulators | KLK7, KLK5, KLKB1 | CYP2A6 2666/4885CA2 2618/4885HDAC10 1524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.